Phase 1/2 study of CybroCell, the first dermal fibroblast cell product for treatment of degenerative disc disease
Latest Information Update: 30 Jan 2020
Price :
$35 *
At a glance
- Drugs Human dermal fibroblasts-SpinalCyte (Primary)
- Indications Intervertebral disc degeneration
- Focus Therapeutic Use
- Acronyms Landmark
- Sponsors FibroGenesis
- 28 Jan 2020 According to a SpinalCyte media release, the company has changed its name to FibroGenesis.
- 28 Mar 2019 According to a SpinalCyte media release, the company announced that the data from this trial will be presented at the 2019 International Society for the Advancement of Spine Surgery Annual Meeting (ISASS19) on Thursday, April 4, 2019 in Anaheim, CA. This will include the new 16th month data.
- 25 Oct 2018 Results of a positive 12 month pain data published in the SpinalCyte Media Release.